Silexion Therapeutics Corp (SLXN) Stock Price, Quote & News

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 674 3430

Fax: 972 2 643 0982

Website: silexion.com

Address:

The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel

Bulllllllllllllllllllll May. 29 at 2:24 PM

$SLXN Keep Buying $10+ R/S Play Squeeze Imminent!

0 · Reply

Bulllllllllllllllllllll May. 29 at 2:20 PM

$SLXN Keep Buying $10+ R/S Play Imminent!

0 · Reply

AlienTrador May. 29 at 1:02 PM

$SLXN this POS just dropped

0 · Reply

AlienTrador May. 29 at 1:02 PM

$SLXN unbelievable

0 · Reply

focafoca99 May. 29 at 11:20 AM

$SLXN executed a 1-for-10 reverse share split, adjusting its warrants and share price effective May 29.

0 · Reply

FreeBeerTomorrow May. 29 at 7:19 AM

$SLXN SLXN- Silexion Therapeutics Corp. implemented a 1-for-10 reverse stock split that officially became effective for the market open this morning, Friday, May 29, 2026. Pre-Split Estimated Float: ~3,850,000 shares Reverse Split Ratio: 1-for-10 Estimated Post-Split Float: ~385,000 shares

0 · Reply

TwongStocks May. 28 at 8:58 PM

Two NASDAQ stocks with reverse splits scheduled on Friday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Friday morning. $HKIT 1 for 3. Will reduce outstanding Class A shares from approx 2.32m to approx 775k. $SLXN 1 for 10. Will reduce outstanding shares from approx 6.19m to approx 619k.

0 · Reply

SaltWaterChickens May. 28 at 5:59 PM

$JTAI $IPW - straight up cash money $SLXN - keeping an eye on this pre/post RS

0 · Reply

FU_Pay_Me_ May. 28 at 12:26 PM

$SLXN This will be a micro float after the split. Here for the pump!

0 · Reply

SaltWaterChickens May. 27 at 9:40 PM

$SLXN $JTAI $DRCT $IPW We like these BS reverse splits - Get ready for Operation (Dennis) Rodman

1 · Reply

Silexion Therapeutics Corp trading halted, news pending

2026-05-26T14:30:18.000Z - 3 days ago

Silexion Therapeutics announces 1-for-10 reverse share split

May 26, 2026, 8:30 AM EDT - 3 days ago

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

2026-05-21T19:20:55.000Z - 7 days ago

3 Penny Stocks to Watch Now, 5/21/26

HCWB MTVA

May 18, 2026, 8:30 AM EDT - 11 days ago

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 15, 2026, 8:27 AM EDT - 14 days ago

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

May 14, 2026, 9:27 AM EDT - 15 days ago

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

2026-05-13T16:35:51.000Z - 15 days ago

Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204

May 13, 2026, 8:00 AM EDT - 16 days ago

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

2026-04-28T14:13:48.000Z - 4 weeks ago

Silexion Therapeutics submits SIL204 clinical trial application to Germany

Apr 28, 2026, 8:45 AM EDT - 4 weeks ago

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

2026-03-24T13:50:15.000Z - 2 months ago

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

Mar 24, 2026, 9:46 AM EDT - 2 months ago

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Mar 17, 2026, 5:01 PM EDT - 2 months ago

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-03-05T13:22:21.000Z - 3 months ago

Silexion Therapeutics urges shareholders to vote ahead of EGM

2026-01-06T12:40:28.000Z - 5 months ago

Silexion Therapeutics issues letter to shareholders

2025-12-16T13:45:35.000Z - 5 months ago

Silexion submits Phase 2/3 trial application to Israel for SIL204

Dec 16, 2025, 8:40 AM EST - 5 months ago

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

2025-12-15T13:00:43.000Z - 5 months ago

Silexion Therapeutics initiated with a Buy at Litchfield Hills

2025-12-02T13:10:13.000Z - 6 months ago

Silexion receives positive feedback from German Health Authority for SIL204

Nov 26, 2025, 7:30 AM EST - 6 months ago

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

2025-11-25T14:20:40.000Z - 6 months ago

Silexion Therapeutics completes toxicology studies for SIL204

Nov 25, 2025, 9:15 AM EST - 6 months ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

2025-11-12T14:06:19.000Z - 7 months ago

Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year

Nov 12, 2025, 9:00 AM EST - 7 months ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-31T21:10:10.000Z - 7 months ago

Silexion Therapeutics files to sell 1.29M ordinary shares for holders

2025-09-30T12:50:48.000Z - 8 months ago

Silexion Therapeutics announces new data in SIL204

Sep 30, 2025, 8:40 AM EDT - 8 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

2025-09-26T20:35:21.000Z - 8 months ago

Silexion Therapeutics files $100M mixed securities shelf

2025-09-25T12:50:46.000Z - 8 months ago

Silexion Therapeutics regains compliance with Nasdaq listing requirements

Sep 25, 2025, 8:45 AM EDT - 8 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

2025-09-11T13:25:36.000Z - 9 months ago

Silexion Therapeutics prices 1.5M shares at $4.00 in public offering

Sep 11, 2025, 9:17 AM EDT - 9 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

2025-09-11T12:15:05.000Z - 9 months ago

Why Is Silexion Therapeutics Stock (SLXN) Up 190% Today?

Sep 11, 2025, 7:00 AM EDT - 9 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 4, 2025, 9:25 AM EDT - 9 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 2, 2025, 8:45 AM EDT - 9 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 PM EDT - 10 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 9:55 AM EDT - 10 months ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 16, 2025, 8:44 AM EDT - 11 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

May 22, 2025, 3:46 PM EDT - 1 year ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 21, 2025, 8:45 AM EDT - 1 year ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 13, 2025, 4:45 PM EDT - 1 year ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 23, 2025, 9:20 AM EDT - 1 year ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 18, 2025, 4:29 PM EDT - 1 year ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 17, 2025, 8:15 AM EDT - 1 year ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 5, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 3, 2025, 8:30 AM EST - 1 year ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Feb 25, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Jan 29, 2025, 5:30 PM EST - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 9:59 AM EST - 1 year ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 28, 2025, 8:29 AM EST - 1 year ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 16, 2025, 11:04 AM EST - 1 year ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 15, 2025, 8:00 PM EST - 1 year ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 4:01 PM EST - 1 year ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 13, 2025, 7:50 AM EST - 1 year ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Bulllllllllllllllllllll May. 29 at 2:24 PM

$SLXN Keep Buying $10+ R/S Play Squeeze Imminent!

0 · Reply

Bulllllllllllllllllllll May. 29 at 2:20 PM

$SLXN Keep Buying $10+ R/S Play Imminent!

0 · Reply

AlienTrador May. 29 at 1:02 PM

$SLXN this POS just dropped

0 · Reply

AlienTrador May. 29 at 1:02 PM

$SLXN unbelievable

0 · Reply

focafoca99 May. 29 at 11:20 AM

$SLXN executed a 1-for-10 reverse share split, adjusting its warrants and share price effective May 29.

0 · Reply

FreeBeerTomorrow May. 29 at 7:19 AM

0 · Reply

TwongStocks May. 28 at 8:58 PM

0 · Reply

SaltWaterChickens May. 28 at 5:59 PM

$JTAI $IPW - straight up cash money $SLXN - keeping an eye on this pre/post RS

0 · Reply

FU_Pay_Me_ May. 28 at 12:26 PM

$SLXN This will be a micro float after the split. Here for the pump!

0 · Reply

SaltWaterChickens May. 27 at 9:40 PM

$SLXN $JTAI $DRCT $IPW We like these BS reverse splits - Get ready for Operation (Dennis) Rodman

1 · Reply

TwongStocks May. 27 at 5:23 PM

$SLXN Equity Corporate Actions Alert #2026 - 359 Information Regarding the Reverse Stock Split, Par Value, and CUSIP Number Change for Silexion Therapeutics Corp (SLXN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-359 Silexion Therapeutics Corp (SLXN) will effect a one-for-ten (1-10) reverse split and par value change of its Ordinary Shares. The reverse stock split and par value change from $0.0135 to $0.135 will become effective on Friday, May 29, 2026. In conjunction with the reverse split, the CUSIP number will change to G1281K148.

0 · Reply

AlienTrador May. 26 at 9:04 PM

$SLXN These Phooking Koonts I bought into this shit....... they sold the last pump and dump to short when it hits $ 4 bucks a share

0 · Reply

NewNewOld May. 26 at 2:39 PM

$SLXN 0,5 warrants holders want keep this up before RS that they can dump shares then 10X

0 · Reply

NewNewOld May. 26 at 1:34 PM

$SLXN reason is that 0,5 warrants get 10x and more dilution. Fraud!

0 · Reply

NewNewOld May. 26 at 1:29 PM

$SLXN you know what happens after RS. DILUTION. DONT BUY THIS SCAM

0 · Reply

ZacksResearch May. 26 at 1:21 PM

"$SLXN just pulled the reverse split trigger — and it’s all about staying on Nasdaq ⚠️ Silexion announced a 1-for-10 reverse share split effective May 29 as it pushes to maintain Nasdaq compliance and strengthen its capital structure ahead of the expected Phase 2/3 trial initiation for SIL204 this quarter. 🧬 Management says the move could reduce volatility, attract a broader investor base, and improve financing flexibility for its KRAS-focused oncology pipeline. See how SLXN’s earnings estimates have been revised lately 👉 " https://www.zacks.com/stock/quote/SLXN/detailed-earning-estimates?cid=sm-stocktwits-0-detailed_estimates-oc-38191&ADID=SYND_STOCKTWITS_TWEET_0_DETAILEDESTIMATES_OC_38191

0 · Reply

NewNewOld May. 26 at 1:14 PM

$SLXN company makes rs 1:10 now that 0,5 warrants get 10x SCAM COMPANY

0 · Reply

NewNewOld May. 26 at 1:04 PM

$SLXN this company makes 1:10 that warrants getting sold 10X pure fraud company. https://finance.yahoo.com/markets/stocks/articles/silexion-therapeutics-announces-1-10-123000401.html

0 · Reply

DARKP00L May. 26 at 1:04 PM

$SLXN 09:03 on May. 26 2026 Silexion Therapeutics shares are trading lower after the company announced a 1-for-10 reverse share split. #tradeideas

0 · Reply

NewNewOld May. 26 at 1:01 PM

$SLXN bankcrypt scam. dont buy.

0 · Reply

NewNewOld May. 26 at 1:00 PM

$SLXN

0 · Reply

TwongStocks May. 26 at 12:32 PM

$SLXN 1 for 10 reverse split, effective May 29. Previously did a 1 for 15 RS on July 28.

0 · Reply

Market Cap	1.74M
Revenue (ttm)	0.00
Net Income (ttm)	-11.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,195,700
Avg Vol	7,067,573
Day's Range	N/A - N/A
Shares Out	4.19M
Stochastic %K	45%
Beta	-0.29
Analysts	Strong Sell
Price Target	$6.00